ABUS vs CPT · P/E 5.4, rev $6.2M vs P/E 104, rev $7.1M
Arbutus Biopharma Corp (ABUS) versus Camden Property Trust (CPT) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Camden Property Trust (CPT) is a reit - residential company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CPT revenue for 2024-12-31 was $7.1M. Net income was $170.8M. Revenue was up 106.8% from 2023-12-31 to 2024-12-31. CPT currently screens at market cap $12.11B and trailing P/E 104.0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CPT currently screens at market cap $12.11B and trailing P/E 104.0.
Not investment advice. Open the ABUS and CPT stock pages for the full models.
Not investment advice.